Protein Information

ID 1574
Name CCL4
Synonyms ACT2; Lag1; SCYA 2; SCYA2; AT744.1; Act2; CCL4; G 26…

Compound Information

ID 1392
Name carbon tetrachloride
CAS tetrachloromethane

Reference

PubMed Abstract RScore(About this table)
17686161 Zhang L, Duan YY, Yin JK, Cui JH, Zhang Y, Cao TS: Grey scale enhancement by a new self-made contrast agent in early cirrhotic stage of rabbit liver. BMC Gastroenterol. 2007 Aug 8;7:32.
BACKGROUND: The development of new ultrasound contrast agents (UCAs) has become one of the most promising fields in ultrasound medicine. This paper evaluates a new self-made contrast agent enhancement effect developed to study the fibrotic stages of the liver in perfusion models in vivo. METHODS: We constructed experimental models of hepatic fibrosis involving five stages from F0 to F4 via administration of CCL4 (0.01 ml/kg BW) every 3 days for 3 months. The intrahepatic circulatory time of the contrast agent was analyzed via an image and Cine-loop display. Calculations of the perfusion-related parameters including the peak signal intensity (PSI) and peak signal intensity time (PIT) of the portal vein and parenchyma were obtained from an analysis of the time-acoustic intensity curve. RESULTS: Hepatic artery to vein transmit time (HA-HVTT) was significantly shorter at F4 stage (mean 5.1 seconds) compared with those in other stages (mean 8.3 s, 7.5 s, 6.9 s, 6.6 s, P < 0.01). The average PSI difference of PV-parenchyma was 13.62 dB in F4 stage, demonstrating significant differences between F4 stage and other early stages (P < 0.001). CONCLUSION: These results indicate that the new self-made contrast agent is capable of indicating intrahepatic hemodynamic changes. HA-HVTT and the PSI difference of the microbubble perfusion in liver parenchyma and PV were considered to differentiate the degree of hepatic fibrosis between F4 and other early stages.
1(0,0,0,1)